Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Curr Opin Obstet Gynecol. 2011 Feb;23(1):31-6. doi: 10.1097/GCO.0b013e3283416477.
Although the use of neoadjuvant chemotherapy (NCT) in breast cancer was once reserved for patients with locally advanced disease or inflammatory breast cancers, it is increasingly used in patients with early-stage tumors. This review outlines the pertinent research in the field over the last year and discusses the clinical implications.
The present review will focus on three evolving areas in the neoadjuvant research field: factors determining response, use of endocrine and biologic therapies, and how to manage patients following response.
NCT in breast cancer is a remarkable research platform providing insight into tumor biology and treatment efficacy in an expedited timeframe. Refining patient selection based on tumor and patient characteristics allows clinicians to limit potentially toxic therapy to those patients expected to receive the greatest benefit. Additionally, exploring new agents and sequencing of regimens based on these characteristics has great potential for impacting local-regional and systemic outcomes. Lastly, as the population of patients undergoing NCT grows, we must constantly adjust our treatment paradigms. We need to monitor them carefully and accurately, understand the implication of a treated tumor for future therapy, and determine how much additional therapy is necessary.
虽然新辅助化疗（NCT）在乳腺癌中的应用曾经仅限于局部晚期疾病或炎性乳腺癌患者，但目前它在早期肿瘤患者中的应用越来越多。本文综述了过去一年中该领域的相关研究，并讨论了其临床意义。
本综述将重点关注新辅助研究领域的三个发展中领域：决定反应的因素、内分泌和生物治疗的应用，以及如何在治疗后管理患者。
乳腺癌 NCT 是一个卓越的研究平台，能够在短时间内深入了解肿瘤生物学和治疗效果。基于肿瘤和患者特征对患者进行选择，可以限制潜在的毒性治疗，只针对那些预期受益最大的患者。此外，基于这些特征探索新的药物和治疗方案的序贯治疗具有很大的潜力，可以影响局部区域和全身的治疗效果。最后，随着接受 NCT 的患者人数不断增加，我们必须不断调整我们的治疗模式。我们需要仔细、准确地监测他们，了解治疗后肿瘤对未来治疗的影响，并确定需要多少额外的治疗。
